Fig. 8
From: Identification and validation of a refined CAF-Associated diagnostic signature in breast cancer
A Comparison of the IHC results for FXYD1 and SULF1 with other markers in malignant breast tissues. In carcinoma in situ (A), FXYD1 expression is notably absent in myoepithelial cells and markedly downregulated in fibroblasts, whereas SULF1 expression undergoes upregulation in fibroblasts. As the disease progresses to invasive carcinoma (B), the absence of FXYD1 expression remains consistent, and the upward trend in SULF1 expression persists. Compared to other markers, these findings provide a more intuitive understanding of the expression patterns.
